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Membrane potentiall screening method that measures the kinetics and potencies of inhibitors of
the yeast multidrug resistance pumps Pdr5p and Snq2p. The assay uses the potentiometric ﬂuorescent probe
diS-C3(3) (as a benchmark substrate of both pumps) to distinguish drugs with minimal effects on plasma
membrane potential as a marker of side-effects on membrane function and integrity. Using FK506, its
structural analog rapamycin and enniatin B, we showed that our assay can also be used to determine the
minimum drug concentration causing an immediate inhibitory effect and to compare the inhibitory
potencies of the drug on the two pumps. We found that the protonophore CCCP effectively inhibits the
transport of diS-C3(3) by both pumps and conﬁrmed the activation of membrane H+-ATPase by CCCP.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionMajor clinical problems in the treatment of cancer are caused by
multidrug resistance (MDR) proteins which expel a variety of
structurally and functionally unrelated anticancer drugs from the
cells [1–3]. Most inhibitors of MDR proteins, especially those targeting
P-glycoprotein exhibit cytotoxicity [4–6].
The major multidrug exporters of S. cerevisiae are the full-size ABC
transporters Pdr5p and Snq2p. They show limited sequence similarity
with mammalian P-glycoprotein and have a reverse order of their
transmembrane and nucleotide-binding domains [7]. Despite these
differences, Pdr5p interacts with many of the same substrates and
inhibitors as P-glycoprotein [8–14]. Thus, yeast Pdr5p can be used to
screen for compounds that may be effective inhibitors of P-glycopro-
tein. Various benchmark substrates of Pdr5p, such as rhodamines [11],
cycloheximide and cerulenin [15], antifungal azoles [13,16], steroids
[14] and others [17,18] have been used in various screeningmodels and
methodologies that have evolved for identiﬁcation and characteriza-
tion of inhibitors/substrates of the pump [11,13,15–17,19].
New efﬁcient inhibitors of MDR pumps found by screening in yeast
may be useful therapeutically in conjunction with current drugs to
combat yeast and bacterial infections and/or malignancies. Combina-
tion therapiesmay result in the usage of drugs at lower concentrations.
All currentyeastscreeningsystemsfor identifyingnewinhibitorsofPdr5p
are based on the same principle — different accumulation of a benchmark
substrate in cells overexpressing Pdr5p (either due to the presence of the
PDR1-3 allele or the presence of a plasmid) in the presence and absence of20 224922797.
ová).
l rights reserved.inhibitors. A lesser amount of the benchmark substrate accumulates in the
absence of inhibitors, while the presence of inhibitors facilitates increased
accumulationwithin cells on the level of an isogenic Pdr5p-deﬁcient strain.
A number of compounds have been found to efﬁciently reduce
Pdr5p's ability to export its benchmark substrates [8,11,13,16,19–22].
Some of them, such as FK506, which have been assumed to be
noncompetitive inhibitors [10,14,15], were later found to be Pdr5p
substrates. Their inhibitory effects are caused by a low efﬂux rate or a
higher afﬁnity for the pump than the benchmark substrate [23].
Themain goal of these screening systems is the identiﬁcation of Pdr5p
inhibitors. However, they also lead to a better understanding of substrate/
pump interactions by providing insight into the structure of the Pdr5p
substrate binding site, the sizes and chemical properties of substrates
[17,18] and the effects of mutations on Pdr5p function [10,23,24].
Ourﬂuorescencemethoduses thepotentiometricﬂuorescentprobe
diS-C3(3) as a benchmark substrate. DiS-C3(3) is a substrate for Pdr5p
and for Snq2p [25]. Our screening system allows us to monitor with
high sensitivityand in real time changes in the activities of bothpumps.
Furthermore, screening is performed on cells in well-deﬁned physio-
logical states, does not require any pretreatment or preincubation and
allows us to monitor effects on cellular membrane potentials. We
present here an efﬁcient strategy for identifying pump inhibitors with
minimal side effects on membrane potential or membrane integrity.
2. Materials and methods
2.1. Yeast strains
Yeast strains used in this study were S. cerevisiae US50-18C (MATα,
PDR1-3, ura3, his1) and its mutants AD1-3 (MATα, PDR1-3, ura3, his1,
718 T. Hendrych et al. / Biochimica et Biophysica Acta 1788 (2009) 717–723yor1Δ::hisG, snq2Δ::hisG, pdr5Δ::hisG), AD12 (MATα, PDR1-3, ura3,
his1, yor1Δ::hisG, snq2Δ::hisG), AD13 (MATα, PDR1-3, ura3, his1,
yor1Δ::hisG, pdr5Δ::hisG) and AD23 (MATα, PDR1-3, ura3, his1,
snq2Δ::hisG, pdr5Δ::hisG) [26].
2.2. Media and cell growth conditions
Yeast was precultured in YPD medium (1% yeast extract, 1%
bactopeptone, 2% glucose) at 30 °C for 24 h. A small volume (1–10 μl)
of inoculum was added to 10 ml fresh YPD medium and the main
culture was grown until it had reached the desired phase of
exponential growth.
2.3. Fluorescence measurement of diS-C3(3) accumulation in cells
Cells from the exponential growth phase were harvested, washed
twice with double-distilled water and resuspended in citrate-
phosphate (CP) buffer of pH 6.0 to OD578=0.1. The potentiometric
probe diS-C3(3) (10−5 M stock solution in ethanol) was added to 3 ml
of yeast cell suspension to a ﬁnal concentration of 2×10−8 M and
ﬂuorescence emission spectra of the cell suspensions were measured
every 2–5 min on FluoroMax - 3 spectroﬂuorimeter (JobinYvon -
groupe HORIBA) equipped with a xenon lamp. Excitation wavelength
was 531 nm, ﬂuorescence range 560–590 nm, duration of one spectral
scan 20 s, scattered light was eliminated by orange glass ﬁlter with a
cutoff wavelength at 540 nm.
The rate and extent of intracellular probe accumulation, a so-called
staining curve, records the dependence of ﬂuorescence emission
maximum wavelength λmax on the time of staining [27,28]. When
appropriate, a tested compound (inhibitor/substrate) was added to a
different ﬁnal concentration during the diS-C3(3) assay (usually after
20 min of staining). The samples were kept at room temperature and
occasionally gently stirred.
2.4. Drug susceptibility assay
Disc diffusion tests were performed as previously described [12]
to determine if compounds are substrates of Pdr5p, Snq2 and Yor1p.
Brieﬂy, yeast cells grown to post-diauxic phase in liquid YPD
medium were washed twice with distilled water and resuspended
in CP buffer (pH 6.0). Then they were diluted into top agar (seeded
with 2.5×106 cells/ml) and poured onto YPG plates (2% agar, 1%
yeast extract, 1% peptone, 2% glycerol). Two types of top agar were
used in this study: (1) 1% YPD agar (1% agar, 1% yeast extract, 1%
peptone, 2% glucose) and (2) 1% YPGE (1% agar, 1% yeast extract, 1%
peptone, 2% glycerol, 2% ethanol). The compounds dissolved inFig. 1. Inhibitory effect of FK506 on Pdr5p. (A) Staining curves of early exponential cells of AD
(triangles). Empty symbols — no FK506 added; full symbols — 5 μM FK506 added at 20 min
(empty circles — no FK506; full squares — 1 μM; full diamonds — 3 μM; full hexagons — 5 μM
squares — no FK506; grey inverted triangles — 10 μM FK506). Arrows with dotted lines indethanol, DMSO, DMF or as aqueous solutions (2 μl) were spotted
onto Whatman paper discs lying on the top of the agar. After 2 days
at 30 °C, the plates were photographed and the size of the growth
inhibition zones measured.
To determine if a compound is able to inhibit the extrusion of a
known substrate (nigericin for Pdr5p and Yor1p, 4-NQO for Snq2p) by
the pumps we used a ‘double addition’mode of the disc diffusion test.
The tested compound (DM-11) was added 15 min after the known
substrate.
2.5. Chemicals
The following materials were purchased from the respective
companies: diS-C3(3) (3,3′-dipropylthiacarboxycyanine), DMSO and
DMF (Fluka), yeast extract (Serva), bactopeptone (Oxoid), glucose
(Penta, Czech Republic), citric acid and Na2HPO4. 12 H2O (reagent
grade) (Lachema, Czech Republic), agar (Dr. Kulich Pharma, Czech
Republic) and glycerol (Lach-Ner, Czech Republic). MDR pump
substrates or inhibitors, lysosomotropic compound and protonophore
used in this study were obtained from the following sources: FK506
and rapamycin (LC Laboratories), enniatin B (Alexis Biochemicals),
nigericin from Streptomyces hygroscopius and CCCP (carbonyl cyanide
3-chlorophenylhydrazone) (Sigma), 4-NQO (N-nitroquinoline 1-
oxide) (Supelco). The lysosomotropic compound DM-11 (2-dodeca-
noyloxyethyl-dimethylammonium chloride) was synthesized in the
laboratory of Prof. S. Witek (Univ. Wroclaw) [29] and kindly provided
by Dr. A. Krasowska.
3. Results and discussion
3.1. Validity of the diS-C3(3) screening assay for identifying inhibitors of
Pdr5 and Snq2 pumps
Our ﬂuorescence assay is based on comparing the accumulation of
the benchmark pump substrate diS-C3(3) in Pdr5p- and/or Snq2p-
expressing cells (strains AD12, AD13 and US50-18C) versus Pdr5p- and
Snq2p-deﬁcient cells (strains AD1-3 and AD23 taken as negative
controls) [25,30] in the absence of an inhibitor and after its addition.
The accumulation of diS-C3(3) in control and inhibitor-treated
cells is recorded as the dependence of the ﬂuorescence emission
maximum wavelength (λmax) on time (see Materials and methods).
λmax(t) reﬂects the intracellular probe concentration at given time t
[31]. Increasing intracellular concentrations are accompanied by a
gradual shift of λmax towards longer wavelengths (a red shift);
probe efﬂux results in a decreased intracellular concentration and a
blue shift [32].1–3 (squares), AD23 (diamonds), AD12 (circles), AD13 (inverted triangles) and US50-18C
. (B) Staining curves of AD12 cells after the addition of different FK506 concentrations
; full triangles — 7 μM; full inverted triangles — 10 μM FK506) and AD1–3 cells (empty
icate FK506 addition.
Fig. 2. Comparison of action of enniatin B and rapamycin with the effect of FK506 on MDR pumps. (A) Staining curves of AD1–3 (squares) and AD12 (circles) mid-exponential cells.
Empty symbols — no inhibitor added; 5 μM enniatin B (full symbols), 5 μM rapamycin (light grey symbols) and 20 μM rapamycin (dark grey symbols) added at 20 min. Dashed line
with crosses — 5 μM FK506 for comparison. (B) Staining curves of AD13 (inverted triangles) cells. Empty symbols — no inhibitor added; 5 μM enniatin B (full symbols) and 20 μM
rapamycin (dark grey symbols) added at 20min. Staining curves of AD1–3 (empty grey squares) and AD12 (empty grey circles) shown for comparison. (C) Staining curves of US50-18C
(triangles) cells. Empty symbols — no inhibitor added; 5 μM enniatin B (full symbols) and 20 μM rapamycin (dark grey symbols) added at 20 min. Staining curves of AD1–3 (empty
grey squares), AD12 (empty grey circles) and AD13 (empty grey inverted triangles) shown for comparison. Arrows with dotted lines indicate drug addition.
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A comparison of staining curves (Fig. 1A) reveals that pump-
expressing cells (strains AD12, AD13 and US50-18C) from an
exponentially growing culture have a lower intracellular concentra-
tion of diS-C3(3) than pump-deﬁcient mutants (AD1-3 and AD23)
used as negative controls. Because the membrane potentials of pump-
deﬁcient and pump-expressing cells in the same phase of growth are
identical [25], the differences in intracellular concentrations of diS-C3
(3) reﬂect probe efﬂux from the cells by the pumps.
The usefulness of diS-C3(3) assay for studying the pump inhibition
potency of drugs was tested with FK506, a known inhibitor/substrate
of the Pdr5 pump [10,14,23]. Addition of 5 μM FK506 to negative
control (AD1-3, AD23) cells does not cause any change in staining (no
effect on membrane potential) (Fig. 1A), while its addition to Pdr5p-Fig. 3. DM-11 does not interact with Pdr5p, Snq2p and Yor1p either as a substrate or as an inh
in variously pump-expressing strains (AD12, AD13, AD23 and US50-18C) and the negative co
(30 mM) and their combinations. (B) Growth inhibition zones measured in a disc diffusion te
US50-18C) and the negative control AD1–3 exposed to 4-NQO (NQO, 3.26 mM; a substrateexpressing AD12 cells leads to the convergence of the staining curve
with that of negative control AD1-3 (and AD23) cells. This indicates
the inhibition of probe efﬂux by Pdr5p.
In contrast to AD12, the staining curve for AD13 cells, which only
express Snq2p, is unaffected by the addition of FK506 (Fig. 1A),
indicating that FK506 has no effect on Snq2p activity.
FK506 addition to parent US50-18C cells having both Pdr5p and
Snq2p causes a λmax increase to the staining level of AD13 cells as a
result of Pdr5p inhibition (Fig. 1A). Hence the ﬂuorescence assay
clearly shows that FK506 interacts only with Pdr5p.
As seen in Fig. 1B, the speed with which the probe concentrations
in the AD12 cells reaches the similar levels as the pump-deﬁcient cells
increases with increasing concentration of FK506. At 7 μM and higher
the staining is no longer dependent on drug concentration and theibitor. (A) Growth inhibition zones measured in a disc diffusion test using YPGE top agar
ntrol AD1–3 exposed to nigericin (NIG, 20 mM; a substrate of Pdr5p and Yor1p), DM-11
st using YPGE top agar in variously pump-overproducing strains (AD12, AD13, AD23 and
of Snq2p), DM-11 (30 mM) and their combinations.
Fig. 4. H+-ATPase inhibitor DM-11 lowers the membrane potential of cells but has no
inﬂuence on the activity of Pdr5p and Snq2p. Staining curves of mid-exponential cells of
negative controls AD1–3 (squares) and AD23 (diamonds), and pump-expressing AD12
(circles), AD13 (inverted triangles) and US50-18C (triangles). Empty symbols — no DM-
11 added; full symbols — 10 μM DM-11 added at 20 min. Arrow with dotted line
indicates DM-11 addition.
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control. This indicates that the staining is given only by membrane
potential [28]. In other words, this concentration is sufﬁcient for an
immediate inhibitory effect. The slower change in staining at low
FK506 concentrations indicates that inhibition of Pdr5p occurs
gradually as the drug passes through the cell wall.
Our assay can determine the minimum drug concentration at
which immediate and complete inhibition occurs.
In determining the usefulness of MDR pump inhibitors, it is also
important to determine whether the inhibitor has effects on
membrane function and integrity. The ﬁrst indicator of such side-
effects is a membrane potential change. Our method permits not only
detection of the pump inhibition by a drug but, independently, also
reveals the effect of the drug on membrane potential. As shown
previously in prestained cells with zero pump activity [33], addition of
drugs can result in changes in λmax. A blue shift indicates plasma
membrane depolarization, while a red shift may signify hyperpolar-
ization or membrane permeabilization. The absence of membrane
potential changes after the addition of FK506 points to its minimal
inﬂuence on membrane function and integrity.
No growth inhibition zones and no difference in survival between
control and FK506-treated cells were observed in disc diffusion and
plating tests (data not shown). Thus FK506, which is known to inhibitFig. 5. The protonophore CCCP causes activation of H+-ATPase. (A) Effect of CCCP and DM-1
Empty squares — no compound added; 1 μM CCCP (full circles), 5 μM CCCP (full triangles) an
DM-11 (downward arrow). The staining curve after addition of 10 μM DM-11 at 20 min (lig
Effect of CCCP and DM-11 additions (irrespective of the sequence) on staining of late-exponen
(cocktail) on staining of late-exponential AD1–3 cells. Full triangles — 5 μM CCCP plus 10 μ
exposed cells. Upward arrow indicates cocktail addition to both variants. Downward arrow
from panel B for comparison (empty triangles — 10 μM DM-11 followed by 5 μM CCCP; grethe transport of some amino acids (predominantly tryptophan)
[10,23,34] does not affect cell survival of our tryptophan prototrophic
strains, even at high concentrations.
We compared the actions of several inhibitors on the pumps to
FK506. Enniatin B is a recently discovered inhibitor of Pdr5p [19].
Rapamycin is a structural analog of FK506 that acts on S. cerevisiae
cells by irreversibly arresting cell in the G1 phase of the cell cycle [35].
Rapamycin has not been tested as a substrate/inhibitor of MDR pumps
in yeast but has been shown to interact with the mammalian P-
glycoprotein [36].
As seen in Fig. 2A, the inhibitory effect of enniatin B is virtually
identical to that of FK506. Inhibition of Pdr5p by 5 μM rapamycin is
much slower than by 5 μM FK506. Inhibition by rapamycin is still
slower at a 4-fold higher concentration. Like FK506, neither of the
two drugs affects the Snq2 pump (Fig. 2B, C) and membrane
potential (Fig. 2A). In view of the structural similarity of FK506 and
rapamycin [36], the rate of passage of both agents through the cell
wall barrier should be similar. The slower staining with 5 μM
rapamycin therefore shows that its ability to inhibit Pdr5p is lower
than that of FK506.
These data demonstrate that our method can be used to compare
the potencies of different inhibitors towards MDR pumps. It should be
noted that the assay assesses in situ and in vivo pump inhibition,
which depends on both pump inhibition and permeability through
the cell wall. These effects can be quantiﬁed by using a suitable
parameter. Given the complex phenomena described here, the
quantiﬁcation will be the subject of a forthcoming study.
3.1.2. Compounds that have no effect on pump activity
As an integral part of assessing the usefulness of our method we
show that compounds that do not interact with the pumps do not
affect the ability of the pumps to transport diS-C3(3) but can only
affect membrane potential. As such compound we used the
lysosomotropic compound DM-11, which was shown to inhibit the
activity of yeast plasma membrane H+-ATPase [29].
Some authors [12, 37] reported that cells deleted in PDR5, SNQ2
and YOR1 become sensitive to DM-11, which thus seems to be a
substrate of Pdr5p, Snq2p and Yor1p. On the other hand, our data
show that DM-11 clearly does not interact with Pdr5p, Snq2p and
Yor1p either as a substrate or as an inhibitor. As seen in the disc
diffusion test on pump-expressing cells (Fig. 3), the zones of
inhibition formed in the presence of Pdr5p and Yor1p substrate
nigericin (Fig. 3A) or the Snq2p substrate 4-NQO (Fig. 3B) plus DM-11
are similar in size to the individual compounds. DM-11 is therefore1 additions (irrespective of the sequence) on staining of early-exponential AD1–3 cells.
d 10 μM CCCP (full inverted triangles) added at 20 min (dotted line) followed by 10 μM
ht grey triangles) followed by 5 μM CCCP (upward arrow) is shown for comparison. (B)
tial AD1–3 cells. Symbols as in panel A. (C) Effect of CCCP addition together with DM-11
M DM-11 added to intact cells, full diamonds — addition of the cocktail to heat-shock-
indicates heat-shock pretreatment. Dotted lines with empty or grey symbols are taken
y triangles — opposite sequence; empty squares — no addition).
Fig. 6. CCCP inhibits diS-C3(3) transport by both Pdr5p and Snq2p independent of H+-ATPase activity. (A) Effect of CCCP and DM-11 additions (irrespective of the sequence) on staining
of mid-exponential Pdr5p-expressing AD12 cells and negative control AD1–3 cells. Empty circles — no compound added to AD12 cells; full circles — 5 μM CCCP added at 12 min to
AD12 cells (dotted line) followed by 10 μM DM-11 (second downward arrow); full diamonds — 10 μM DM-11 added at 12 min to AD12 cells followed by 5 μM CCCP (upward arrow).
Empty squares— no compound added to AD1–3 cells; grey squares— 5 μM CCCP added at 12 min to AD1–3 cells followed by 10 μMDM-11 (ﬁrst downward arrow); grey diamonds—
10 μMDM-11 added at 12 min to AD1-3 cells followed by 5 μMCCCP (ﬁrst downward arrow). (B) Effect of CCCP and DM-11 additions (irrespective of the sequence) on staining of mid-
exponential Snq2p-expressing AD13 cells compared with negative control AD1–3 cells. Empty inverted triangles— no compound added to AD13 cells; full inverted triangles— 5 μM
CCCP added at 12 min to AD13 cells (dotted line) followed by 10 μM DM-11 (downward arrow); full diamonds — 10 μM DM-11 added at 12 min to AD13 cells followed by 5 μM CCCP
(upward arrow). Staining curves and symbols for AD1–3 cells are the same as in panel A (C) Effect of CCCP and DM-11 additions (irrespective of the sequence) on staining of mid-
exponential Pdr5p- and Snq2p-expressing US50-18C cells compared with negative control AD1-3 cells. Empty triangles — no compound added to US50-18C cells; full triangles —
5 μMCCCP added at 12min to US50-18C cells (dotted line) followed by 10 μMDM-11 (downward arrow); full diamonds— 10 μMDM-11 added at 12min to US50-18C cells followed by
5 μM CCCP (upward arrow). Staining curves and symbols for AD1–3 cells are the same as in panel A.
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caused by DM-11 in the triple pump deletant AD1–3 and in pump-
expressing strains AD12, AD13, AD23 and US50-18C indicates that
DM-11 is not a substrate of Pdr5p, Snq2p or Yor1p.
Fluorescence measurements (Fig. 4) reveal that the effect of DM-11
indeed involves lowering of the membrane potential in negative
controls (AD1–3, AD23). The decrease in λmax after the addition of
DM-11 reﬂects the extent of inhibition of the H+-ATPase. Cells of
Pdr5p- and/or Snq2p-expressing strains in the same growth phase
display the same drop in staining relative to the DM-11 untreated
controls. Hence DM-11 does not affect the activity of the pumps, i.e.
their ability to export the probe from the cells.
3.2. Protonophore CCCP causes activation of H+-ATPase and interacts
with both Pdr5p and Snq2p
In early exponential AD1–3 cells, in which the probe accumulates
solely according to membrane potential, addition of different
concentrations of CCCP does not cause any decrease in staining
(Fig. 5A). The highest concentration even causes a slight increase inFig. 7. CCCP is a substrate of both Pdr5p and Snq2p. (A) Growth inhibition zones measured
AD13, AD23 and US50-18C) and negative control AD1–3 exposed to 10mMCCCP. (B) Growth i
expressing strains (AD12, AD13, AD23 and US50-18C) and the negative control AD1–3 expoλmax. This is surprising since the protonophore should dissipate
membrane potential and cause depolarization.
The increase in staining after CCCP addition is still more striking in
late exponential cells (Fig. 5B) that have a lower membrane potential
[25]. This increase in staining is concentration-dependent, i.e. the
same staining level is attained faster at a higher CCCP concentration.
The most likely explanation for this increase in staining is an
increase in membrane potential. CCCP is a lipophilic, weak acid [38]
that causes intracellular acidiﬁcation and induces a rapid activation of
the H+-ATPase. Activation of the H+-ATPase has been reported byweak
acids [39] and by medium chain fatty acids [40]. A CCCP-induced
activation of this enzyme has been described by dos Passos et al. [41].
The participation of the inducible pump Pdr12p, which recognizes
CCCP as a substrate (Goffeau, A., personal communication), can be
excluded because the export of CCCP anions should not increase the
membrane potential [42,43]. In addition, our cultivation and experi-
mental conditions practically exclude a high level of this transporter in
the plasma membrane [42]. Induction of Pdr12p, regulated by the
War1p transcription factor [44] (but not by Pdr1p and Pdr3p [42]), is
observed only under stress caused by some weak organic acids [45].in a disc diffusion test using YPD top agar in variously pump-expressing strains (AD12,
nhibition zonesmeasured in a disc diffusion test using YPGE top agar in variously pump-
sed to 5 mM CCCP.
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note that prior inhibition of the H+-ATPase with DM-11 prevents the
increase in λmax by a subsequent addition of CCCP. Rather, addition of
CCCP leads to a marked depolarization and the staining level is the
same as attained with the opposite sequence of additions (Fig. 5A, B).
The CCCP-induced activation of the H+-ATPase is an important
observation because CCCP is commonly used as a diagnostic tool to
indicate cell integrity. CCCP should not be used as the sole marker of
cell integrity, but rather it should be used in combination with DM-11
or another H+-ATPase blocker. We illustrate the use of DM-11 plus
CCCP for determining cell integrity in Fig. 5C. The staining proﬁle of
late exponential cells after the simultaneous addition of DM-11 and
CCCP (taken from Fig. 5B) is compared to the response of heat shocked
cells. In contrast to intact cells, cocktail addition to the heat shocked
cells does not cause any drop in the high cell staining. This indicates
the membrane-potential-independent interaction of the probe with
the components of permeabilized cells [33].
CCCP addition to Pdr5p- and/or Snq2p-expressing cells causes a
variably fast increase inλmax and a convergence of their staining curves
with that of the negative control AD1–3 (Fig. 6). We can attribute this
effect to a differential ability of CCCP to inhibit probe transport by the
two pumps. Although the activity of the two pumps is comparable (the
staining levels for strains AD12 and AD13 are practically the same), the
rate of λmax increase in the case of AD13 cells having only Snq2p is
much higher than the rate observed in the AD12 strain (Pdr5p).We can
attribute this effect to a different ability of CCCP to inhibit the probe
transport by the two pumps. The rate of staining observed with strain
US50-18C (overproducing both pumps) is a combination of these two
effects. Subsequent addition of DM-11 to CCCP-treated cells shows that
the cells are intact and behave as a negative control.
This is another important ﬁnding in addition to the H+-ATPase
activation,whichof course takesplace also in the Pdr5p- and/or Snq2p-
overproducing strains. The CCCP-induced inhibition of probe transport
by both pumps is documented in Pdr5p- and/or Snq2p-overproducing
cells inwhich an activation ofH+-ATPase had beenpreventedbyDM-11
(Fig. 6). Even in this case the addition of CCCP is accompanied in all
strains by λmax increase to the level of negative control.
To determine how CCCP inhibits probe export by the pumps, we
performed disc diffusion tests (Fig. 7) using both types of top agar (see
Materials and methods). In YPD agar, the cells will be growing on a
fermentable carbonsource andpumpactivitywill behigh [25] (Fig. 7A).
The absence of zones in Pdr5p- and/or Snq2p-expressing strains AD12,
AD13 and US50-18C in contrast to AD1-3 and AD23 clearly shows that
CCCP is a substrate ofbothPdr5pandSnq2p. In Fig. 7B,whereYPGEagar
contains a non-fermentable carbon source [11,12], CCCP is a much
weaker substrate of Pdr5p than of Snq2p. The growth inhibition zones
for strains having Snq2p (AD13, US50-18C) are much smaller than
those for AD1-3 and AD23. The zones for AD12 and AD1–3 have almost
the same size but a different “clarity”. The negligible difference in the
appearance of zones for AD12 and AD1–3 is not given by an extremely
low level of Pdr5p in AD12 cells (in comparison with that of AD13)
because under the same growth conditions nigericin is still effectively
expelled from the cells (see Fig. 3A).
The ﬁnding that CCCP interacts with both Pdr5p and Snq2p points
to another important diagnostic application of our ﬂuorescence
screening system. Namely, the method makes it possible not only to
detect if a compound inhibits the probe transport by both pumps but
can also document the different ability of the compound to inhibit
each of the pumps.
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